Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC

NCT06861894 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

164

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG: Adebrelimab and nab-paclitaxel and carboplatin
RADIATION: Radiation
PROCEDURE: standard oesophagectomy
OTHER: active surveillance

Sponsor

Zhigang Li